SGC-CBP30
|
|
- CAS号:
- 1613695-14-9
- 英文名:
- SGC-CBP30
- 英文别名:
- CS-993;SGCBP30;CS-1923;SGC-CBP30;SGCBP30;SGCCBP 30;SGCCBP30;SGC CBP30;SGC-CBP30 USP/EP/BP;(S)-4-(1-(2-(3-Chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-;2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-4-isoxazolyl)-1-[(2S)-2-(4-morpholinyl)propyl]-1H-benzimidazole;1H-Benzimidazole, 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-4-isoxazolyl)-1-[(2S)-2-(4-morpholinyl)propyl]-
- 中文名:
- SGC-CBP30
- 中文别名:
- 化合物SGC-CBP30;CREBBP/EP300抑制剂(SGC-CBP30);2-[2-(3-氯-4-甲氧基苯基)乙基]-5-(3,5-二甲基-4-异恶唑基)-1-[(2S)-2-(4-吗啉基)丙基]-1H-苯并咪唑
- CBNumber:
- CB52670792
- 分子式:
- C28H33ClN4O3
- 分子量:
- 509.04
- MOL File:
- 1613695-14-9.mol
|
|
|
SGC-CBP30化学性质
-
沸点:
-
678.0±55.0 °C(Predicted)
-
|
-
密度:
-
1.28±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
≥20.05 mg/mL in DMSO; ≥25.7 mg/mL in EtOH with ultrasonic; ≥4.67 mg/mL in H2O with ultrasonic
-
|
-
酸度系数(pKa):
-
6.98±0.10(Predicted)
-
|
-
形态:
-
powder
-
|
-
颜色:
-
white to beige
-
|
SGC-CBP30性质、用途与生产工艺
SGC-CBP30是强效的CREBBP/EP300抑制剂,IC50分别为21 nM 和 38 nM。
作为一个CREBBP/ EP300-选择性化学探针,SGC-CBP30在U2OS细胞和HeLa 细胞中显示中度的细胞毒性。
CREBBP/ EP300-选择性化学探针。
SGC-CBP30是强效的CREBBP/EP300抑制剂,无细胞试验中IC50分别为21 nM 和 38 nM。对CBP的选择性分别是对BRD4(1)和BRD4(2)选择性的40倍和250倍。
Target | Value |
CREBBP
(Cell-free assay)
|
21 nM
|
EP300
(Cell-free assay)
|
38 nM
|
作为一个CREBBP/ EP300-选择性化学探针,SGC-CBP30在U2OS细胞和HeLa 细胞中显示中度的细胞毒性。
SGC-CBP30
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/08/19 | HY-15826 | SGC-CBP30 | | 1 mg | 617元 |
2024/08/19 | HY-15826 | SGC-CBP30 SGC-CBP30 | 1613695-14-9 | 2mg | 837元 |
1613695-14-9, SGC-CBP30 相关搜索:
- Inhibitors
- 抗疟配体
- 细胞生物学试剂
- 小分子抑制剂,天然产物
- C28H33ClN4O3
- 化合物SGC-CBP30
- CREBBP/EP300抑制剂(SGC-CBP30)
- 2-[2-(3-氯-4-甲氧基苯基)乙基]-5-(3,5-二甲基-4-异恶唑基)-1-[(2S)-2-(4-吗啉基)丙基]-1H-苯并咪唑
- 1613695-14-9
- inhibit,IL-17A,HAT,HATs,BRD,Histone Acetyltransferase,ankylosing,SGCCBP30,cells,epigenetic,spondylitis,anti-inflammatory,arthritis,SGC-CBP30,Epigenetic Reader Domain,SGC-CBP-30,Th17,psoriatic,SGC CBP30,Inhibitor
- (S)-4-(1-(2-(3-Chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)propan-2-yl)morpholine
- SGC-CBP30 USP/EP/BP
- 1H-Benzimidazole, 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-4-isoxazolyl)-1-[(2S)-2-(4-morpholinyl)propyl]-
- SGCCBP30;SGC CBP30
- CS-993
- SGCBP30;SGCCBP 30
- SGCBP30
- CS-1923
- (S)-4-(1-(2-(3-Chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-
- 2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-4-isoxazolyl)-1-[(2S)-2-(4-morpholinyl)propyl]-1H-benzimidazole
- 2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole
- 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-4-isoxazolyl)-1-[(2S)-2-(4-morpholinyl)propyl]-1H-benzimidazole SGC-CBP30
- 2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole
- SGC-CBP30